Article Text
Statistics from Altmetric.com
- angina
- unstable
- anticholesteremic agents
- heptanoic acids
- myocardial infarction
- pravastatin
- pyrroles
- hydroxymethylglutaryl-CoA reductase inhibitors
Q In patients with an acute coronary syndrome (ACS), is standard dose pravastatin non-inferior to high dose atorvastatin for reducing death or major cardiovascular (CV) events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆
METHODS
Design:
randomised, placebo controlled trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] trial).
Allocation:
concealed.*
Blinding:
blinded (clinicians and patients).*
Follow up period:
mean 24 months.
Setting:
349 sites in 8 countries.
Patients:
4162 stable patients (mean age 58 y, 78% men) who were hospitalised for an ACS in the previous 10 days, were enrolled after a percutaneous revascularisation procedure (if planned), and had a total cholesterol concentration ⩽240 mg/dl (6.21 mmol/l) taken within the first 24 hours, or <6 months …